Colgate-Palmolive Company (NYSE:CL - Free Report) - Research analysts at Zacks Research increased their FY2026 EPS estimates for shares of Colgate-Palmolive in a research report issued to clients and investors on Friday, November 13th. Zacks Research analyst Team now forecasts that the company will post earnings per share of $3.91 for the year, up from their prior forecast of $3.85. The consensus estimate for Colgate-Palmolive's current full-year earnings is $3.92 per share. Zacks Research also issued estimates for Colgate-Palmolive's Q4 2026 earnings at $0.98 EPS, Q1 2027 earnings at $0.97 EPS, Q2 2027 earnings at $1.02 EPS, Q3 2027 earnings at $1.01 EPS, Q4 2027 earnings at $1.06 EPS, FY2027 earnings at $4.06 EPS, Q1 2028 earnings at $1.05 EPS, Q2 2028 earnings at $1.09 EPS, Q3 2028 earnings at $1.10 EPS and FY2028 earnings at $4.38 EPS.
Colgate-Palmolive (NYSE:CL - Get Free Report) last issued its quarterly earnings results on Friday, October 30th. The company reported $0.97 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.93 by $0.04. The business had revenue of $5.37 billion for the quarter, compared to analyst estimates of $5.34 billion. Colgate-Palmolive had a net margin of 9.65% and a return on equity of 607.88%. Colgate-Palmolive's revenue for the quarter was up 4.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.91 EPS.
Several other equities analysts also recently issued reports on CL. Piper Sandler cut their target price on Colgate-Palmolive from $98.00 to $95.00 and set an "overweight" rating on the stock in a research report on Monday, September 21st. Barclays raised their target price on Colgate-Palmolive from $87.00 to $95.00 and gave the stock an "equal weight" rating in a research note on Tuesday, November 3rd. JPMorgan Chase & Co. lowered their price target on Colgate-Palmolive from $104.00 to $102.00 and set an "overweight" rating for the company in a research report on Monday, November 2nd. TD Cowen boosted their price target on Colgate-Palmolive from $90.00 to $97.00 and gave the company a "hold" rating in a research note on Monday, November 2nd. Finally, Raymond James Financial increased their price objective on Colgate-Palmolive from $100.00 to $102.00 and gave the company an "outperform" rating in a report on Monday, August 3rd. Thirteen equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $101.22.
View Our Latest Research Report on Colgate-Palmolive
Colgate-Palmolive Trading Down 0.1%
NYSE:CL opened at $99.62 on Monday. Colgate-Palmolive has a 12 month low of $75.96 and a 12 month high of $101.18. The firm has a fifty day simple moving average of $90.94 and a 200-day simple moving average of $90.29. The company has a current ratio of 0.96, a quick ratio of 0.63 and a debt-to-equity ratio of 11.23. The company has a market capitalization of $79.19 billion, a P/E ratio of 39.07, a PEG ratio of 4.51 and a beta of 0.31.
Colgate-Palmolive Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Friday, November 13th. Shareholders of record on Tuesday, October 20th were paid a dividend of $0.53 per share. The ex-dividend date was Tuesday, October 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.1%. Colgate-Palmolive's dividend payout ratio (DPR) is presently 83.14%.
Insider Buying and Selling
In other Colgate-Palmolive news, COO Panagiotis Tsourapas sold 19,938 shares of Colgate-Palmolive stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $98.74, for a total transaction of $1,968,678.12. Following the completion of the transaction, the chief operating officer owned 9,111 shares in the company, valued at approximately $899,620.14. This trade represents a 68.64% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Hazlin sold 23,376 shares of the business's stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $99.15, for a total value of $2,317,730.40. Following the completion of the transaction, the insider directly owned 27,021 shares of the company's stock, valued at approximately $2,679,132.15. This trade represents a 46.38% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 77,414 shares of company stock worth $7,613,786. Corporate insiders own 0.43% of the company's stock.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the stock. State Street Corp grew its position in shares of Colgate-Palmolive by 97.4% during the 2nd quarter. State Street Corp now owns 94,195,992 shares of the company's stock valued at $8,635,889,000 after acquiring an additional 46,476,510 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Colgate-Palmolive by 8.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 13,532,417 shares of the company's stock valued at $1,240,652,000 after purchasing an additional 1,010,872 shares in the last quarter. First Eagle Investment Management LLC increased its stake in shares of Colgate-Palmolive by 1.1% in the 2nd quarter. First Eagle Investment Management LLC now owns 8,205,699 shares of the company's stock valued at $752,298,000 after purchasing an additional 88,917 shares in the last quarter. Bank of America Corp DE raised its holdings in Colgate-Palmolive by 17.4% in the 1st quarter. Bank of America Corp DE now owns 6,637,597 shares of the company's stock worth $565,722,000 after purchasing an additional 986,063 shares during the period. Finally, Amundi raised its holdings in Colgate-Palmolive by 19.9% in the 2nd quarter. Amundi now owns 6,218,257 shares of the company's stock worth $570,090,000 after purchasing an additional 1,033,918 shares during the period. 80.41% of the stock is owned by institutional investors and hedge funds.
Key Headlines Impacting Colgate-Palmolive
These are some of the CL headlines that stood out recently:
- Positive Sentiment: A valuation analysis argues that Colgate-Palmolive shares may be about 21% below fair value, which could support investor interest if the estimate proves accurate. Colgate Palmolive (CL) Stock May Be 21% Below Fair Value Today
- Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to $3.91 from $3.85 and made smaller increases to FY2027 ($4.06) and FY2028 ($4.38) forecasts. These revisions offer a modestly constructive earnings signal, though they are one analyst’s estimates. Zacks Research earnings estimate revisions
- Neutral Sentiment: The estimate changes were mixed: Zacks raised some quarterly forecasts but lowered others, including Q1 2027 and Q1–Q2 2028. That tempers the positive full-year revisions and does not indicate a broad upgrade to near-term expectations. Zacks Research quarterly earnings estimate revisions
Colgate-Palmolive Company Profile
(
Get Free Report)
Colgate-Palmolive is a global consumer products company whose business spans oral care, personal care, home care and pet nutrition. Its products include toothpaste, toothbrushes, mouthwashes, soaps, shampoos, cleaning products and pet food. The company's best-known brands include Colgate, Palmolive, elmex, Softsoap, Ajax and Hill's Pet Nutrition. It sells products through retail and other channels in markets around the world. Founded in 1806 by William Colgate as a soap and candle business in New York City, the company has grown into an international manufacturer of household and personal care products.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Colgate-Palmolive, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Colgate-Palmolive wasn't on the list.
While Colgate-Palmolive currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.